EP3986396A4 - Compositions et méthodes de traitement du surdosage aigu aux cannabinoïdes avec un antagoniste des récepteurs cannabinoïdes - Google Patents

Compositions et méthodes de traitement du surdosage aigu aux cannabinoïdes avec un antagoniste des récepteurs cannabinoïdes Download PDF

Info

Publication number
EP3986396A4
EP3986396A4 EP20827604.8A EP20827604A EP3986396A4 EP 3986396 A4 EP3986396 A4 EP 3986396A4 EP 20827604 A EP20827604 A EP 20827604A EP 3986396 A4 EP3986396 A4 EP 3986396A4
Authority
EP
European Patent Office
Prior art keywords
cannabinoid
compositions
methods
receptor antagonist
overdose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20827604.8A
Other languages
German (de)
English (en)
Other versions
EP3986396A1 (fr
Inventor
Phil Skolnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opiant Pharmaceuticals Inc
Original Assignee
Opiant Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/704,699 external-priority patent/US20200179271A1/en
Application filed by Opiant Pharmaceuticals Inc filed Critical Opiant Pharmaceuticals Inc
Publication of EP3986396A1 publication Critical patent/EP3986396A1/fr
Publication of EP3986396A4 publication Critical patent/EP3986396A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP20827604.8A 2019-06-18 2020-06-17 Compositions et méthodes de traitement du surdosage aigu aux cannabinoïdes avec un antagoniste des récepteurs cannabinoïdes Pending EP3986396A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962862832P 2019-06-18 2019-06-18
US201962862830P 2019-06-18 2019-06-18
US16/704,699 US20200179271A1 (en) 2018-12-07 2019-12-05 Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist
US202063037351P 2020-06-10 2020-06-10
PCT/US2020/038211 WO2020257333A1 (fr) 2019-06-18 2020-06-17 Compositions et méthodes de traitement du surdosage aigu aux cannabinoïdes avec un antagoniste des récepteurs cannabinoïdes

Publications (2)

Publication Number Publication Date
EP3986396A1 EP3986396A1 (fr) 2022-04-27
EP3986396A4 true EP3986396A4 (fr) 2023-08-02

Family

ID=74040920

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20827604.8A Pending EP3986396A4 (fr) 2019-06-18 2020-06-17 Compositions et méthodes de traitement du surdosage aigu aux cannabinoïdes avec un antagoniste des récepteurs cannabinoïdes

Country Status (4)

Country Link
EP (1) EP3986396A4 (fr)
AU (1) AU2020295410A1 (fr)
IL (1) IL289066A (fr)
WO (1) WO2020257333A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11471437B2 (en) 2019-06-18 2022-10-18 Opiant Pharmaceuticals, Inc. Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2010018856A1 (ja) * 2008-08-13 2012-01-26 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
WO2013068371A1 (fr) * 2011-11-08 2013-05-16 Intervet International B.V. Compositions à forme posologique douce à mâcher d'antagonistes des récepteurs de cannabinoïdes de type 1 (cb-1)
US20150313868A1 (en) * 2012-12-18 2015-11-05 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
WO2016007616A1 (fr) * 2014-07-09 2016-01-14 Eip Pharma, Llc Procédés de traitement de troubles neurologiques
GB2551986A (en) * 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
US20200179271A1 (en) * 2018-12-07 2020-06-11 Opiant Pharmaceuticals, Inc. Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARK D BLACK ET AL: "AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents", PSYCHOPHARMACOLOGY, SPRINGER, BERLIN, DE, vol. 215, no. 1, 22 December 2010 (2010-12-22), pages 149 - 163, XP019895061, ISSN: 1432-2072, DOI: 10.1007/S00213-010-2124-0 *

Also Published As

Publication number Publication date
EP3986396A1 (fr) 2022-04-27
IL289066A (en) 2022-02-01
AU2020295410A1 (en) 2022-01-20
WO2020257333A1 (fr) 2020-12-24

Similar Documents

Publication Publication Date Title
EP3890724A4 (fr) Compositions et procédés de traitement d'un surdosage aigu au cannabinoïde avec un antagoniste du récepteur cannabinoïde
EP3950575A4 (fr) Dispositif, procédé et programme
EP3814341A4 (fr) Inhibiteurs de récepteurs erbb
EP3770289A4 (fr) Acier résistant à l'usure et son procédé de production
EP3979947A4 (fr) Procédés, dispositifs et compositions pour une administration locale
EP4034167A4 (fr) Procédés et compositions pour le traitement d'une maladie ou d'un trouble
EP3790557A4 (fr) Compositions et méthodes pour améliorer la distorsion de brin
EP3967432A4 (fr) Foret hélicoïdal
EP3789123A4 (fr) Dispositif d'enduction et procédé d'enduction
EP4026382A4 (fr) Procédés et appareils de fonctionnement en liaison latérale
EP3938514A4 (fr) Composés et méthodes de réduction de l'expression de kcnt1
EP3989496A4 (fr) Dispositif de détermination de politique, procédé de détermination de politique et programme
EP3856253A4 (fr) Méthodes et compositions pour le traitement d'un trouble à médiation par un codon d'arrêt prématuré
EP3929188A4 (fr) Composé antagoniste de pd-l1
EP4006842A4 (fr) Dispositif d'évaluation de fissures, procédé d'évaluation de fissures et programme d'évaluation de fissures
EP3928713A4 (fr) Dispositif, méthode et programme d'évaluation
EP3979609A4 (fr) Dispositif d'évaluation, procédé d'évaluation et programme
IL289066A (en) Preparations and methods for treating acute cannabinoid overdose using a cannabinoid receptor antagonist
EP4083032A4 (fr) Composé antagoniste de pd-l1
EP4056570A4 (fr) Inhibiteur d'eed, son procédé de préparation et son utilisation
EP4077831A4 (fr) Déflecteur de tuyau de descente
EP3842808A4 (fr) Appareil de gestion d'administration, procédé de gestion d'administration et programme
IL289068A (en) Preparations and methods for the treatment of cannabinoid hyperemesis syndrome using a cannabinoid receptor antagonist
EP3932490A4 (fr) Agent antiprurigineux utilisant un antagoniste du récepteur pac1
EP4083879A4 (fr) Dispositif d'évaluation, procédé d'évaluation, et programme d'évaluation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40074663

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031352000

Ipc: A61K0009000000

A4 Supplementary search report drawn up and despatched

Effective date: 20230703

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/10 20170101ALI20230628BHEP

Ipc: A61K 47/44 20170101ALI20230628BHEP

Ipc: A61K 47/26 20060101ALI20230628BHEP

Ipc: A61K 47/14 20170101ALI20230628BHEP

Ipc: A61P 39/02 20060101ALI20230628BHEP

Ipc: A61P 25/36 20060101ALI20230628BHEP

Ipc: A61K 31/415 20060101ALI20230628BHEP

Ipc: A61K 31/397 20060101ALI20230628BHEP

Ipc: A61K 31/352 20060101ALI20230628BHEP

Ipc: A61K 9/00 20060101AFI20230628BHEP